Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions

Journal of Clinical Oncology

Volumn 28, Issue 35, 2010, Pages 5166-5173

  Sloand, Elaine M ^a   Olnes, Matthew J ^a   Shenoy, Aarthie ^a   Weinstein, Barbara ^a   Boss, Carol ^a   Loeliger, Kelsey ^a   Wu, Colin O ^a   More, Kenneth ^a   Barrett, A John ^a   Scheinberg, Phillip ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; HLA DR15 ANTIGEN; THYMOCYTE ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE THROMBOCYTOPENIA; BACTERIAL PNEUMONIA; BLOOD CELL COUNT; CANCER REGRESSION; CARDIOVASCULAR SYMPTOM; CELLULITIS; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; HAND EDEMA; HEADACHE; HEMATOPOIESIS; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA; MALE; METABOLIC DISORDER; MOLLUSCUM CONTAGIOSUM; MONOTHERAPY; MUSCLE CRAMP; MYCOBACTERIOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; ORCHITIS; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PILONIDAL SINUS; PRIORITY JOURNAL; PRURITUS; RASH; RIGIDITY; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OFF-LABEL USE; PILOT PROJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650354414     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.7010     Document Type: Article

References (41)

1. Joosten E, Pelemans W, Hiele M, et al: Prevalence and causes of anaemia in a geriatric hospitalized population. Gerontology 38:111-117, 1992
2. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 109:1536-1542, 2007 (Pubitemid 46595689)
3. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004 (Pubitemid 38900045)
4. Pomeroy C, Oken MM, Rydell RE, et al: Infection in the myelodysplastic syndromes. Am J Med 90:338-344, 1991
5. Jädersten M, Malcovati L, Dybedal I, et al: Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613, 2008
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
7. Sloand EM, Wu CO, Greenberg P, et al: Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26:2505-2511, 2008
8. List AF: New approaches to the treatment of myelodysplasia. Oncologist 7:39-49, 2002 (suppl 1)
9. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
10. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002 (Pubitemid 34525728)
11. Rosenfeld S, Follmann D, Nunez O, et al: Antithymocyte globulin and cyclosporine for severe aplastic anemia: Association between hematologic response and long-term outcome. JAMA 289:1130-1135, 2003 (Pubitemid 37430327)
12. Geary CG, Harrison CJ, Philpott NJ, et al: Abnormal cytogenetic clones in patients with aplastic anaemia: Response to immunosuppressive therapy. Br J Haematol 104:271-274, 1999 (Pubitemid 29083333)
13. Jonásova A, Neuwirtová R, Cermák J, et al: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100:304-309, 1998 (Pubitemid 28131061)
14. Lim ZY, Killick S, Germing U, et al: Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21:1436-1441, 2007 (Pubitemid 46965284)
15. Killick SB, Mufti G, Cavenagh JD, et al: A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 120:679-684, 2003
16. Shimamoto T, Ohyashiki K: Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma 44:593-604, 2003 (Pubitemid 36304816)
17. Broliden PA, Dahl IM, Hast R, et al: Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91:667-670, 2006 (Pubitemid 43799466)
18. Stadler M, Germing U, Kliche KO, et al: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465, 2004 (Pubitemid 38425859)
19. Bennett WM: The nephrotoxicity of new and old immunosuppressive drugs. Ren Fail 20:687-690, 1998
20. Saunthararajah Y, Nakamura R, Wesley R, et al: A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102:3025-3027, 2003 (Pubitemid 37248879)
21. Elter T, Kilp J, Borchmann P, et al: Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 94:150-152, 2009
22. Fraser G, Smith CA, Imrie K, et al: Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 14:96-109, 2007 (Pubitemid 47204237)
23. Thieblemont C, Bouafia F, Hornez E, et al: Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 45:711-714, 2004 (Pubitemid 38256030)
24. Scheinberg P, Fischer SH, Li L, et al: Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109:3219-3224, 2007 (Pubitemid 46578057)
25. Lorenzi AR, Clarke AM, Wooldridge T, et al: Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes. Arthritis Rheum 58:370-375, 2008 (Pubitemid 351294871)
26. Knechtle SJ: Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 8:106-112, 2004
27. Matteson EL, Yocum DE, St Clair EW, et al: Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 38:1187-1193, 1995
28. Isaacs JD, Manna VK, Rapson N, et al: CAMPATH-1H in rheumatoid arthritis: An intravenous dose-ranging study. Br J Rheumatol 35:231-240, 1996
29. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
30. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006 (Pubitemid 44061337)
31. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
32. Geller N, Leifer LS, Follmann D, et al: Design of early trials in stem cell transplantation: A hybrid frequentist-Bayesian approach, in Geller N (ed): Advances in Clinical Trials Biostatistics New York, NY, Marcel Dekker, 2004
33. Calado RT, Young NS: Telomere maintenance and human bone marrow failure. Blood 111:4446-4455, 2008
34. Calado RT, Yewdell WT, Wilkerson KL, et al: Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 114:2236-2243, 2009
35. Willis F, Marsh JC, Bevan DH, et al: The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 114:891-898, 2001 (Pubitemid 32953751)
36. Genestier L, Fournel S, Flacher M, et al: Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 91:2360-2368, 1998 (Pubitemid 28155510)
37. Waldmann H, Hale G: CAMPATH: From concept to clinic. Philos Trans R Soc Lond B Biol Sci 360:1707-1711, 2005 (Pubitemid 43997819)
38. Kim H, Min YJ, Baek JH, et al: A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 33:222-231, 2009
39. Sloand EM, Yong AS, Ramkissoon S, et al: Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 103:14483-14488, 2006 (Pubitemid 44484776)
40. Pellagatti A, Hellström-Lindberg E, Giagounidis A, et al: Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 142:57-64, 2008 (Pubitemid 351783162)
41. Li J, Tan J, Zhuang L, et al: Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res 67:11317-11326, 2007 (Pubitemid 350248558)